{"analyses":[{"ciLowerLimit":"6.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"24.7","estimateComment":"Miettinen \\& Nurminen method stratified by geographic region (Asia vs RoW) \\& tumor histology (SCC vs adenocarcinoma/Siewert type I adenocarcinoma of the EGJ)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0006","pValueComment":"One-sided p-value for testing. H0: difference in %=0; H1: difference in %\\>0.","paramType":"Difference in Percentages","paramValue":"15.1","statisticalMethod":"Miettinen & Nurminen method"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.1","upperLimit":"30.5","value":"21.5"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"12.1","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants with a PD-L1 CPS ≥10 who experienced a CR or PR is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received Investigator's choice of paclitaxel 80-100 mg/m\\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The efficacy analysis population consisted of all randomized participants with a PD-L1 CPS ≥10. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Through Final Analysis data cutoff date of 15-Oct-2018 (up to approximately 34 months)","title":"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}